Finance Should Own the Number and Not the Operating Model

Gross-to-Net is treated as a close process because that is where it becomes visible. It is downstream of everything that created it.

Finance should own the number. The operating model belongs to a cross-functional forum with real decision rights, reviewed monthly and reset quarterly. A stable blended Gross-to-Net rate is the metric that creates the most false confidence, because it hides leakage at specific points in the patient journey.

Why it gets treated as a Finance process

Because that is where it becomes visible, and because the calendar rewards it. Accruals are due, auditors ask questions, and the answer has to reconcile. None of that is wrong. It is just downstream of everything that created the number.

The connections run in one direction

• A contracting decision sets rebate economics.
• Channel design determines who takes title, and therefore what chargebacks look like.
• Both feed the price points that government programs calculate from, which is where Best Price, AMP and ASP exposure originates.
• 340B compounds the consequences on both the economic and the operational side.
• Payer behavior determines whether coverage translates into utilization.
• Copay and affordability design determine whether utilization translates into a started patient.
• Specialty pharmacy design determines what you can see about any of it.

Every one of those is a commercial decision with a financial echo. Finance records the consequences, months later.

Ownership and cadence

Finance should own the number and must not own the operating model. The operating model needs a standing cross-functional forum with real decision rights, chaired by someone senior enough that Commercial, Market Access, Trade, Government Pricing, Patient Services and Finance all show up.

Shared accountability is required for anything that changes a price point, anything that changes who takes title, anything that changes patient out-of-pocket, and anything that changes what data the organization will be able to see afterward. That last one is almost always decided by accident.

The essentials are transaction-level visibility rather than summarized reporting, a single set of assumptions that all functions forecast from, controls that are auditable because the process was standardized before it was automated, and a monthly cadence with a quarterly reset. Anything slower and you are reconciling history.

When the objectives conflict

They conflict constantly, and the honest answer is that you sequence rather than balance. Compliance is not tradeable. After that, I would rather protect access and accept a worse Gross-to-Net rate than protect the rate and lose the patient, because a patient who never starts therapy generates no revenue to have a rate on. That is not idealism. It is arithmetic.

The metrics that create false confidence

The blended Gross-to-Net rate is the figure most likely to mislead, because a stable aggregate can sit directly on top of real leakage at a specific point in the journey. Gross sales growth has the same problem. So does a coverage percentage, which tells you a formulary decision was won and nothing about whether patients started.

What I would rather a CEO look at is conversion at each stage of the journey, the gap between projection and prediction rather than only what reconciled, and the proportion of approved patients who never activate. That last one is the closest single number to the thesis, and almost nobody reports it.

A stable blended Gross-to-Net rate is not evidence of health. It is the least comfortable assumption I challenge, because it is the one my own side of the table relies on.

Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.